 LEXINGTON, Mass., June 04, 2021 GLOBE NEWSWIRE -- Agenus NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data demonstrating the differentiation of balstilimab as an anti-PD-1 antibody as well as data from a Phase 1 clinical trial of AGEN2373, a CD137 agonist antibody, at the American Society of Clinical Oncology ASCO Annual Meeting 2021 from June 4 8, 2021. 